Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-17T00:19:52.439Z Has data issue: false hasContentIssue false
  • English
  • Français

Future Treatment of Parkinson’s Disease

Published online by Cambridge University Press:  18 September 2015

Joseph King Ching Tsui
Joseph King Ching Tsui*
Affiliation:
Division of Neurology, Department of Medicine, University of British Columbia, Vancouver
*
Division of Neurology, Department of Medicine, University Hospital – UBC Site, 2211 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 1W5
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

New methods of drug delivery and slowing down the progression of Parkinson’s disease (PD) are the major goals of research. More steady drug levels in the blood are possible by means of controlled-release preparations of levodopa and long-acting dopamine agonists, as well as transcutaneous duodenal tubes and pumps for controlled subcutaneous infusion. Patches containing dopamine agonists absorbed through the skin may be developed. The role of D1 agonists as compared with D2 agonists remains to be elucidated. Agonists on autoreceptors of dopaminergic neurons may potentially reduce excessive stimulation of the intact neurons and this may slow down the rate of neuronal death in PD. Monoamine oxidase-B inhibitors may have a potentially protective action on neurons. Investigations are being carried out to evaluate this claim. Catechol-o-methyl-transferase inhibitors may be helpful in theory. There is also recent interest in inhibitors of excitatory amino acids, which may contribute to neuronal loss in PD.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 19 , Issue S1: 3rd Canadian Conference on Neurodegenerative Diseases , February 1992 , pp. 160 - 162
Copyright
Copyright © Canadian Neurological Sciences Federation 1992

References

1.Marsden, CD, Parkes, JD.Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet 1977; 1: 345–349.CrossRefGoogle ScholarPubMed
2.Calne, DB, Teychenne, PF, Claveria, LE, et al. Bromocriptine in parkinsonism. Br Med J 1974; 4: 442–444.CrossRefGoogle ScholarPubMed
3.Langston, JW, Ballard, PA.Parkinsonism induced by l-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson’s disease. Can J Neurol Sci 1984; 11: 160–165.CrossRefGoogle Scholar
4.Calne, DB, Langston, JW.Aetiology of Parkinson’s disease. Lancet 1983; 2: 1457–1459.CrossRefGoogle ScholarPubMed
5.Madrazo, I, Drucker-Colin, R, Diaz, V, et al. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with Parkinson’s disease. N Engl J Med 1987; 316: 831–834.CrossRefGoogle Scholar
6.Lindvall, O, Backlund, E-O, Farde, L, et al. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson’s disease. Exp Brain Res 1986; 65: 235–240.Google Scholar
7.Birkmayer, W, Hornykiewicz, O.Der l-dioxyphenylalanin-(=l-dopa)-Effekt bei der Parkinson-Akinesie. Wien Klin Wochenschr 1961; 73: 787–788.Google Scholar
8.Barbeau, A, Sourkes, TL, Murphy, GR.Les catecholamines dans la maladie de Parkinson. In: De Ajuriaguerra, J, ed. Monoamines et systeme nerveux central. Paris: Masson, 1962: 247–262.Google Scholar
9.Papavasiliou, PS, Cotzias, GC, Duby, SE, et al. Levodopa in parkinsonism: potentiation of central effects with a peripheral inhibitor. N Engl J Med 1972; 286: 8–14.CrossRefGoogle ScholarPubMed
10.Pinder, RM, Brogden, RN, Sawyer, PR, et al. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism. Drugs 1976; 11: 329–377.CrossRefGoogle ScholarPubMed
11.Markham, CH, Diamond, SG.Evidence to support early levodopa therapy in Parkinson’s disease. Neurology 1981; 31: 125–131.CrossRefGoogle Scholar
12.Fahn, S, Bressman, S.Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984; 11 (suppl): 200–206.CrossRefGoogle ScholarPubMed
13.Calne, DB.Current views on Parkinson’s disease. Can J Neurol Sci 1983; 10: 11–15.CrossRefGoogle ScholarPubMed
14.Calne, DB, Rinne. Controversies in the management of Parkinson’s disease. Movement Disorders 1986; I, 3: 159–162.CrossRefGoogle Scholar
15.Tetrud, J, Langston, JW.The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 1989; 245: 519–522.CrossRefGoogle ScholarPubMed
16. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N. Engl J Med 1989; 321: 1364–1371.CrossRefGoogle Scholar
17.Mena, I, Cotzias, GC.Protein intake and treatment of Parkinson’s disease with levodopa. N Engl J Med 1975; 292: 181–184.CrossRefGoogle ScholarPubMed
18.Tsui, JK, Ross, S, Poulin, K, et al. The effect of dietary protein on the efficacy of L-dopa: a double-blind study. Neurology 1989; 39: 549–552.CrossRefGoogle ScholarPubMed
19.Cedarbaum, JM, Breck, L, Kutt, H, et al. Sinemet CR-4 in the treatment of response fluctuations in Parkinson’s disease. Ann Neurol 1986; 20: 121.Google Scholar
20.Goetz, CG, Tanner, CM, Carrol, VS, et al. Controlled-release carbidopa/levodopa combination. Neurology 1986; 36 (suppl 1): 217.Google Scholar
21.Lewitt, PA.Clinical and pharmacological aspects of the antiparkinsonian ergolene lisuride. In: Fahn, CD, Marsden, CD, Jenner, P, et al., eds. Recent Developments in Parkinson’s Disease. New York: Raven Press, 1986: 347–354.Google Scholar
22.Sage, JI, Duvoisin, RC.Long-term efficacy of pergolide in patients with Parkinson’s disease. Ann Neurol 1985; 18: 137.Google Scholar
23.Obeso, JA, Luquin, MR, Martinez-Lage, JM.Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease. Lancet 1986; 1: 467–470.CrossRefGoogle ScholarPubMed
24.Obeso, JA, Luquin, MR, Vaamonde, J.Continuous dopaminergic stimulation for Parkinson’s disease. Can J Neurol Sci 1987; 14: 488–492.CrossRefGoogle ScholarPubMed
25.Hughes, AJ, Lees, AJ, Stern, GM.Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 1990; 336: 32–34.CrossRefGoogle ScholarPubMed
26.Stoessl, AJ, Mak, E, Calne, DB.(+)-4-propyl-9-hydroxynaphthox-azine (PHNO), a new dopaminomimetic in treatment of parkinsonism. Lancet 1987; 2: 1330–1331.Google Scholar
27.Rupniak, NMJ, Tye, SJ, Jennings, CA, et al. Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. Neurology 1988; 39: 329–335.CrossRefGoogle Scholar
28.Jori, MC, Franceschi, M, Giusti, MC, et al. Cabergoline: a new ergoline derivative with long-lasting dopaminergic properties. Ital J Neurol Sci 1987; S5: 61.Google Scholar
29.Stoof, JC, Kebabian, JW.Opposing roles for D1 and D2 dopamine receptors in efflux of cAMP for rat neostriatum. Nature 1981; 294: 366–368.CrossRefGoogle Scholar
30.Barone, P, Braun, AR, Chase, TN.D-1/D-2 dopamine receptor interactions in the regulation of extrapyramidal motor functions: studies in animal models and parkinsonian patients. Clin Neuropharmacol 1986; 9 (supp 4): 129–130.Google ScholarPubMed
31.Barone, P, Bankiewicz, KS, Corsini, GU, et al. Dopaminergic mechanisms in hemiparkinsonian monkeys. Neurology 1987; 37: 1592–1595.CrossRefGoogle ScholarPubMed
32.Tsui, JKC, Wolters, ECH, Peppard, RF, et al. A double-blind, place-bo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208–243 in patients with Parkinson’s disease. Neurology 1989; 39: 856–858.CrossRefGoogle Scholar
33.Landau, WM.Clinical Neuromythology IV – pyramid sale in the bucket shop: DATATOP bottoms out. Neurology 1990; 40: 1337–1339.CrossRefGoogle Scholar
34.Nutt, J, Woodward, WR.3-O-methyldopa and the response to levodopa. Ann Neurol 1987; 21: 584–588.CrossRefGoogle ScholarPubMed
35.Cedarbaum, JM, Leger, G, Reches, A, et al. Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys. Clin Neuropharmacol 1990; 13: 544–552.CrossRefGoogle ScholarPubMed
36.Southern, PA, Powis, G.Free radicals in medicine II. Involvement in human disease. Mayo Clin Proc 1988; 63: 390–408.CrossRefGoogle Scholar
37.Hall, ED, McCall, JM, Yonkers, PA, et al. A non-glucocorticoid analog of methylprednisolone duplicates its high dose pharmacology in models of CNS trauma and neuronal membrane damage. J Pharmacol Exp Ther 1987; 242: 137–142.Google Scholar
38.Meldrum, B.Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters. Clin Sci 1985; 68: 113–122.CrossRefGoogle ScholarPubMed
39.Miller, AA, Sawyer, DA, Roth, B, et al. In: Meldrum, B, Porter, RJ, eds. New Anticonvulsant Drugs: 12 Lamotrigine. England: John Libbey & Co Ltd., 1986: 165–177.Google ScholarPubMed